Morgan Stanley Starts Theravance Inc. (THRX) at Underweight, Sees 38% Downside
Tweet
Share
E-mailGet Alerts THRX Hot Sheet
Price: $4.06 --0%
Rating Summary:
6 Buy, 5 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
6 Buy, 5 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Morgan Stanley initiates coverage on Theravance Inc. (NASDAQ: THRX) with a Underweight with a $12 price target, which suggests 38% downside.
For an analyst ratings summary and ratings history on Theravance Inc. click here. For more ratings news on Theravance Inc. click here.
Shares of Theravance Inc. closed at $19.37 yesterday.
For an analyst ratings summary and ratings history on Theravance Inc. click here. For more ratings news on Theravance Inc. click here.
Shares of Theravance Inc. closed at $19.37 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Starts Definium Therapeutics Inc (DFTX) at Buy
- BTIG Starts Freenome Inc. (FRNM) at Buy
- JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
